BRAF and melanoma: It has been previously shown that some BRAFi/MEKi-resistant BRAF V600-mutant melanoma cells strongly upregulate PAK signaling and become dependent on PAK signaling for survival to varying degrees, such that certain pan-PAK inhibitors may be cytotoxic to BRAFi/MEKi-resistant cells in the absence of BRAF inhibitors [5].